MAKO Surgical Corp. Announces Definitive Agreement to Be Acquired by Stryker Corporation for $30 per Share in Cash

MAKO Surgical Corp. (MAKO) today announced a definitive agreement with Stryker Corporation (SYK), by which Stryker will acquire all of the outstanding shares of MAKO for $30.00 per share in cash, for an aggregate purchase price of approximately $1.65 billion.

"The combination of Stryker's established industry leadership with MAKO's innovative products and people contains the power to positively transform orthopedics," said Maurice R. Ferre, M.D., President and Chief Executive Officer. "It is with this in mind that MAKO's board of directors unanimously voted to recommend that MAKO's shareholders vote in favor of it."

Read more: MAKO Surgical Corp ( MAKO )

Retractable Technologies, Inc. Announces Verdict

Retractable Technologies, Inc. (NYSE MKT: RVP), a leading maker of safety medical devices, announced today that a Tyler, Texas jury returned a verdict in the litigation of Retractable Technologies, Inc. v. Becton, Dickinson and Company in favor of Retractable. After a six year battle, the verdict vindicates Retractable’s claim that industry giant Becton, Dickinson and Company illegally engaged in anticompetitive conduct with the intent to acquire or maintain monopoly power in the safety syringe market and engaged in false advertising under the Lanham Act. The jury awarded Retractable $113,508,014 in compensatory damages subject to being trebled pursuant to federal statute. Retractable is represented by Locke Lord LLP; Ireland, Carroll & Kelley, P.C.; and Jim Parsons Law.

Read more: Retractable Technologies Inc ( RVP )

Sunshine Heart Implants First Patient in C-Pulse(R) COUNTER HF(TM) U.S. Pivotal Trial

Sunshine Heart, Inc. (SSH) announced today the first patient implant in the Company's U.S. pivotal trial, COUNTER HF. The COUNTER HF study is a prospective, randomized, multi-center, controlled trial that will evaluate the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure. Integral to the COUNTER HF study is the assessment of C-Pulse's unique balloon counterpulsation treatment designed to improve heart function and reduce re-hospitalizations due to worsening heart failure.

Read more: Sunshine Heart Inc ( SSH )

Rochester Medical to be Acquired by C. R. Bard for Approximately $262 Million

Rochester Medical Corporation (ROCM) today announced it has entered into a definitive merger agreement with C. R. Bard, Inc. (BCR) at a price of $20 per share, or approximately $262 million in the aggregate. The Rochester Medical Board of Directors unanimously approved the agreement and will recommend that the Company's shareholders approve the transaction.

Under the terms of the merger agreement, Rochester Medical shareholders will receive $20 in cash for each share that they hold at the closing of the merger, representing a 37 percent premium over the Company's average closing price during the 90 trading days ended September 3, 2013. The acquisition is subject to certain closing conditions specified in the definitive agreement, including regulatory approvals and the approval of Rochester Medical's shareholders. The transaction is expected to close in the fourth calendar quarter of 2013.

Read more: Rochester Medical Corporation ( ROCM )

Stereotaxis Announces Renewal of Silicon Valley Bank Credit Facility

Stereotaxis, Inc. (STXS) announced today that it has completed the renewal of its revolving credit facility with Silicon Valley Bank (SVB).

Under an amended credit agreement, Stereotaxis will extend its $3 million asset based revolving line of credit with SVB through March 31, 2014. The amended credit agreement eliminates the $3 million of available advances guaranteed by Alafi Capital Company and an affiliate of Sanderling Venture Partners, and the guarantees have been terminated. Furthermore, the prepayment premium on its term note was eliminated from the agreement, allowing the Company to repay the outstanding amount under this facility prior to its maturity date of December 2013, without penalty.

Read more: Stereotaxis Inc ( STXS )